Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

Pharmaceutical giant Eli Lilly & Co. (LLY) has announced that its newest obesity drug called Retatrutide delivered what ...

Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of their body weight while reducing osteoarthritis pain.

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...